JD.COM
JD.COM is at a price level where we expect buying interest to build.

JD.COM is at a price level where we expect buying interest to build.

Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
Stronger-than-expected results from Meta, Microsoft and Alphabet last week helped investor sentiment. It was interesting to see Amazon warning over lackluster growth in its cloud-computing business.
This week we look to key earnings calls by Apple, AMD and Qualcomm to shape overall price action.
With average S&P500 EPS tracking at $52+ for the quarter, there is no immediate risk, and our fair valuation range of 4200 for the S&P500 index looks about right.

Our US S&P100 Trade Table is up 9.1% year-to-date and Eli Lilly is among the best performers after being closed out for an 18.8% gain, over 48 days. The highlighted OHLC bars show the entry and exit points.
To enquire about our automated execution of the Trade Table signals, please call 1300 614 002.


Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
Direxion Daily Pharmaceutical & Medical Bull 3X
22/4 update: PILL is now up 10% and looks to have further to run.



JD.COM is approaching a price level where we expect buying interest to pick up. Watch for an initial turn higher in the stochastic
